Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06733441 · ClinicalTrials.gov registry record · Phase 1
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
A Phase 1 study of Lymphoma, sponsored by Treeline Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT06733441: Recruiting Phase 1 study of Lymphoma, sponsored by Treeline Biosciences.
NCT06733441 is a Phase 1 study of Lymphoma that is actively recruiting participants, run by Treeline Biosciences. The registered enrollment target is 50 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06733441, a Phase 1 study of Lymphoma, is actively recruiting participants, sponsored by Treeline Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Conditions Studied
Interventions
- DRUG TLN-254
Study Locations (5)
California
- Stanford Cancer Institute - Stanford
Missouri
- Washington University School of Medicine - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
British Columbia
- British Columbia Cancer Agency - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 1 |
What NCT06733441 shows while recruiting
NCT06733441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which TLN-254 is the first listed.
NCT06733441 lists 5 locations in 5 states (California, Missouri, New York).
Frequently Asked Questions
What is clinical trial NCT06733441 about?
NCT06733441 is a clinical study titled "A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma". The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
What is the current status of trial NCT06733441?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-12-16. Estimated completion is 2028-11-15.
What conditions does trial NCT06733441 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT06733441?
The interventions under investigation include: TLN-254 (DRUG).
Who is sponsoring clinical trial NCT06733441?
This trial is sponsored by Treeline Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06733441 being conducted?
This trial has 5 study locations across California, Missouri, New York, Tennessee, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06733441's enrollment target sits among peer trials
50 148th of 299 higher than 145 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI